Communiqués Fosun International Limited

Actions

656 HK0656038673

Conglomérats spécialisés dans les biens de consommation

Temps Différé Hong Kong S.E. 05:49:29 08/09/2026			Varia. 5j.	Varia. 1 janv.
5,175 ^HKD	-0,58%		-3,09%	+18,04%

07/09	Fosun Pharma prévoit un rachat d'actions de 1 milliard de HK$ financé par la cession d'une participation dans Gland Pharma	MT
07/09	Une filiale de Fosun International cède 6% de Gland Pharma pour 28 milliards de roupies	MT

Communiqués

04:49	Fosun International : Hang Seng Sustainability Rating Climbs to AA+, Setting a New Record	PU
04/09	AM Best Affirms Credit Ratings of Peak Reinsurance Company Limited and Its Subsidiaries	AQ
31/08	Fosun International: ClubMed Lifestyle Group Proposes Hong Kong Listing, Targeting 85 Resorts Globally by 2030	AQ
02/07	Corporate Governance Asia’s CEOs Interview: Fosun: “Innovation” and “Globalization” in Action, Creating a Sustainable Impact	PU
10/06	Fosun International : Henlius’ Serplulimab Approved for Perioperative Gastric Cancer, Pioneering a Chemotherapy-Sparring Adjuvant Approach	PU
29/05	Fosun International : Henlius' Pertuzumab Approved in China, Solidifying Breast Cancer Strategy as the First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination	PU
14/05	Fosun International : Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer’s Disease	PU
08/05	Fosun International : Henlius’ HLX43 (anti-PD-L1 ADC) Receives PMDA’s Acknowledge to Initiate Global Phase 2/3 Trial in sqNSCLC	PU
28/04	Fosun International : ESG Report 2025	PU
30/03	Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%，Aiming to Achieve“RMB10 Billion in Profit”	PU
30/03	Guo Guangchang’s Letter to Shareholders: “Repair the Roof While the Sun Is Shining” — Fosun Aims to Go Further with Greater Stability	PU
30/03	Fosun International : 2025 Annual Results Presentation	PU
13/03	Fosun International : and HSBC China Sign Strategic Cooperation Agreement	PU
12/03	Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs	AQ
09/03	Fosun International : Key Takeaways from Fosun International’s Investor Communication Meeting on March 8, 2026	PU
09/03	Fosun International: One-Off Non-Cash Impairment Provisions for Certain Non-Core Businesses, Core Industries Maintain Sound Development Momentum	AQ
27/02	Fosun International : Receives “Certificate of Excellence in Environmental, Social and Governance Reporting” from Hong Kong Management Association	PU
30/12	Fosun’s Story 2025: Every Step of the Climb	PU
21/11	Fosun International : Honored as “ESG Leading Enterprise” by Bloomberg Businessweek/Chinese Edition	PU
08/11	Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation	PU
23/10/25	Fosun International : Henlius Completes Patient Enrolment in the U.S. Bridging Study of Serplulimab in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	PU
17/10/25	Wang Qunbin: Innovation-Driven, Fosun’s Path to Globalization	PU
13/10/25	Fosun International : Signs Strategic Cooperation Agreement with BNP Paribas	PU
09/10/25	Fosun International : S&P Global CSA Score Rises to 72, Retains Industry Lead	PU
15/09/25	Fosun International : Achieves AA- in HSI ESG Rating for Third Consecutive Year, Marks Sixth Year as Constituent of Hang Seng Corporate Sustainability Benchmark Index	PU